Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Study of Xolair in Subjects With Moderate to Severe Persistent Asthma (EXTRA)


A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair in Subjects With Moderate to Severe Persistent Asthma Who Are Inadequately Controlled With High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists




This is a multicenter, randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of subcutaneously administered Xolair as add-on therapy to high-dose ICS+LABA for the treatment of subjects aged 12-75 years old diagnosed with moderate to severe asthma who are inadequately controlled with high-dose ICS+LABA.

Study Status: Recruiting

Dottie Vasas 216-445-4847

Condition Intervention Phase
Asthma Drug: omalizumab
Drug: placebo
Drug: corticosteroids
Drug: long-acting beta-agonists
Phase 3

Verified by Genentech April, 2008

Sponsored by: Genentech
Information provided by: Genentech identifier: NCT00314574

Study Type: Interventional

Study Design: Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

Karin Rosen, M.D., Ph.D.., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site